Article Text

PDF
THU0518 Biological therapy in non-systemic juvenile idiopathic arthritis patients followed in adult rheumatology department: hur-bio real life results
  1. L Kilic1,
  2. A Sari1,
  3. B Armagan1,
  4. A Erden1,
  5. Ö Karadag1,
  6. A Akdogan1,
  7. S Apras Bilgen1,
  8. S Kiraz1,
  9. S Ozen2,
  10. U Kalyoncu1,
  11. AI Ertenli1
  1. 1Department of Rheumatology
  2. 2Department of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey

Abstract

Background Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disorder in childhood and more than one-third of patients have active inflammation during adult years that can cause disability.

Objectives To define the demographic and clinical characteristics of non-systemic JIA (ns-JIA) patients under biological therapy followed in adult rheumatology department.

Methods Hacettepe University Biologic Registry (HUR-BIO) is a single center biological registry since 2005. HUR-BIO database includes demographic and clinical characteristics of patients, disease activity parameters, history of articular prosthesis. The use of biological agents in routine rheumatology practice has been approved by the Ministry of Health since 2003.

Results In this study, 95 (72.6% women) ns-JIA patients were included. The demographic and clinical characteristics of the patients were shown in the table. The first biological agents were; Etanercept (63.2%), adalimumab (16.8%), infliximab (12.6%) and the others 7 (7.4%). After a mean follow-up of 60 (48) months, 42 (44.2%) patients required biologic switch. The last visit HAQ scores of 75 patients were known and 16 (21.3%) patients had HAQ score ≥1.0 (female 15/54 vs. male 1/21, p=0.029). The last visit DAS-28 score of 72 patients was known and 46 (63.9%) patients had remission or low disease activity. 14 patients (14.7%) had history of articular prosthesis and were all female. Patients with history of articular prosthesis were older [39.1±10.1 vs. 29.6±10.3 years, p<0.0001], had longer disease duration [25.7±6.6 vs. 17.2±11.9 years, p=0.001] and had longer time until the biological therapy [19.6±8.4 vs. 11.5±11.6 years, p=0.002]. The time until the biological therapy of 38 ns-JIA patients diagnosed after 2003 was shorter [3.2±2.9 vs. 19.4±10.6 years, p<0.001].

Table 1.

The Demographic and Clinical Characteristics of the ns-JIA Patients

Conclusions Structural damage and history of articular prosthesis was more common in female ns-JIA patients receiving biological therapy. Functional disability and disease activity were also higher in female patients. On the other hand, the follow-up ns-JIA patients had a good level of remission and low disease activity.The shorter duration until the time of biological treatment in patients diagnosed after 2003 indicates that both pediatric and adult rheumatologists have begun to treat these patients more effectively.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.